AstraZeneca PLC (LON:AZN)
13,802
-232 (-1.65%)
Nov 17, 2026, 4:37 PM GMT
AstraZeneca Revenue
AstraZeneca had revenue of $16.21B USD in the quarter ending September 30, 2026, with 6.70% growth. This brings the company's total for the last twelve months to $62.38B, up 7.32% year-over-year. In the year 2025, AstraZeneca had annual revenue of $58.74B with 8.63% growth. That makes AstraZeneca the 199th largest company in the world by revenue and 6th in the United Kingdom.
Revenue (ttm)
$62.38B
Revenue Growth
+7.32%
P/S Ratio
4.56
Revenue / Employee
$649.16K
Employees
96,100
Market Cap
214.08B GBP
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full AstraZeneca breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 58.74B | 4.67B | 8.63% |
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | 24.38B | 2.29B | 10.38% |
| Dec 31, 2018 | 22.09B | -375.00M | -1.67% |
| Dec 31, 2017 | 22.47B | -537.00M | -2.33% |
| Dec 31, 2016 | 23.00B | -1.71B | -6.90% |
| Dec 31, 2015 | 24.71B | -1.84B | -6.93% |
| Dec 31, 2014 | 26.55B | 741.00M | 2.87% |
| Dec 31, 2013 | 25.81B | -2.17B | -7.75% |
| Dec 31, 2012 | 27.97B | -5.62B | -16.72% |
| Dec 31, 2011 | 33.59B | 322.00M | 0.97% |
| Dec 31, 2010 | 33.27B | 465.00M | 1.42% |
| Dec 31, 2009 | 32.80B | 1.20B | 3.81% |
| Dec 31, 2008 | 31.60B | 2.04B | 6.91% |
| Dec 31, 2007 | 29.56B | 3.08B | 11.65% |
| Dec 31, 2006 | 26.48B | 2.53B | 10.54% |
| Dec 31, 2005 | 23.95B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GSK plc | 33.54B |
| Haleon | 11.15B |
| Smith & Nephew | 4.77B |
| Hikma Pharmaceuticals | 2.58B |
| Convatec Group | 1.88B |
| Spire Healthcare Group | 1.58B |
| CVS Group | 712.80M |
| Genus | 658.10M |
AstraZeneca News
- 1 day ago - AstraZeneca PLC Announces Baxfendy Recommended for Approval in the EU - Nasdaq
- 1 day ago - AstraZeneca PLC Receives US FDA Approval for Imfinzi Combination in Muscle-Invasive Bladder Cancer - Nasdaq
- 1 day ago - AstraZeneca PLC Announces EU Approval of Klygefa for Generalised Myasthenia Gravis - Nasdaq
- 1 day ago - AstraZeneca fends off lawsuit over alleged Soliris drug monopoly - Reuters
- 1 day ago - Summit's FDA Setback Is a Reality Check for Next-Gen Cancer Drugs - Barrons
- 1 day ago - AstraZeneca Cuts 600 U.S. Sales Jobs At Cost-Saving Program Takes Effect - Nasdaq
- 1 day ago - AstraZeneca, Alexion announce Klygefa approved in EU - TheFly
- 1 day ago - AstraZeneca: Alexion's Klygefa Gets EU Approval To Treat Adults With Generalised Myasthenia Gravis - Nasdaq